{"id":"W4414642437","doi":"10.1182/bloodadvances.2025017244","title":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in <i>FLT3</i> -mutated AML","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Thomas Hospital","funders":"RCPA Foundation; Blood Cancer UK; Astellas Pharma; National Cancer Research Institute; Servier; Amgen; Pfizer; Cancer Research UK; Royal College of Pathologists of Australasia","keywords":"Gemtuzumab ozogamicin; Midostaurin; Cytarabine; Myeloid leukemia; Cumulative incidence; Chemotherapy; Induction chemotherapy; Fms-Like Tyrosine Kinase 3; Concomitant","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001329369,0.0003746197,0.001054121,0.0002114345,0.0001936789,0.0005110516,0.0004551506,0.0005348659,0.0008941657],"category_scores_gemma":[0.001352465,0.0001933206,0.0005157573,0.0002710207,0.0004362774,0.0004607326,0.0002714925,0.001301259,0.0001766121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006493544,"about_ca_system_score_gemma":0.0005360868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004440391,"about_ca_topic_score_gemma":0.0009371195,"domain_scores_codex":[0.9994875,0.0002998361,0.00004183037,0.00005145185,0.00005267199,0.00006666077],"domain_scores_gemma":[0.9992282,0.0002043647,0.0002463586,0.00005680608,0.00002528454,0.0002389635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7005061,0.0103563,0.03230079,0.0004771956,0.001229055,0.0002301486,0.0001626959,0.003301974,0.03922526,0.0002617568,0.001522933,0.2104258],"study_design_scores_gemma":[0.1989788,0.645628,0.1230765,0.0001325483,0.001659228,0.001115604,0.00009068539,0.005706598,0.01844814,0.0003824597,0.004731075,0.0000503861],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974689,0.001594006,0.0001792082,0.0001136179,0.0000300486,0.00009152632,0.0001014911,0.00001654265,0.000404482],"genre_scores_gemma":[0.9988492,0.0003953277,0.0001974753,0.00009428014,0.00003542968,0.00006845362,0.000216286,0.000003301778,0.0001403248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001329369,"threshold_uncertainty_score":0.007030427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007209435744216486,"score_gpt":0.2814725213016392,"score_spread":0.2742630855574227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}